Bharat Biotech completes phase 3 trials of Covid-19 nasal vaccine

19 June, 2022 | Pravina Srivastava

Bharat Biotech on Saturday announced that the COVID-19 nasal vaccine's clinical phase III studies have been finished

Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday announced that the COVID-19 nasal vaccine’s clinical phase III studies have been finished, and the business would submit its results to the Drugs Controller General of India (DCGI) next month.

Dr Ella remarked that “We recently concluded a clinical experiment and are currently analysing the results. We will submit the data to the regulatory authorities next month. If all goes well, we will be granted authorization to introduce the world’s first clinically validated COVID-19 nasal vaccination.”

Krishna was speaking at Viva Technology 2022 in Paris, where India was named nation of the year.

Bharat Biotech was granted authorization to perform independent phase III studies on its COVID-19 nasal vaccination by India’s drug controller in January of this year.

Krishna stated that people who have taken the second dosage of COVID-19 must also take the booster dose.

According to data from the Union Health Ministry, India recorded 12,899 new COVID-19 cases on Sunday, with 15 deaths.

India reported 13,216 new infections in the last 24 hours on Saturday, breaking the 13,000 threshold for the first time in more than three months. Since the outbreak of the COVID pandemic in India in March 2020, the country’s COVID infection count has risen to 43,296,692.

India’s current caseload has risen to 72,474 from over 12,000 new cases, accounting for 0.17 percent of all cases.

Meanwhile, India has recorded 8,518 recoveries in the last 24 hours, bringing the overall number of recoveries to 4,26,99,363. Currently, the recovery rate is 98.62 per cent.